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a b s t r a c t
Objective: To compare the efficacy of a new dentifrice containing 1.5% arginine, an insoluble
calcium compound and 1450 ppm fluoride to arrest and reverse naturally occurring buccal
caries lesions in children relative to a positive control dentifrice containing 1450 ppm
fluoride alone.
Study design: Participants fromChengdu, Sichuan Province, China tested three dentifrices: a
new dentifrice containing 1.5% arginine, an insoluble calcium compound, and 1450 ppm
fluoride, as sodium monofluorophosphate, a positive control dentifrice containing
1450 ppm fluoride, as sodium fluoride, in a silica base, and a matched negative control
dentifrice without arginine and fluoride. Quantitative Light-induced Fluorescence (QLF) was
used to assess buccal caries lesions at baseline and after 3 and 6 months of product use.
Results: 438 participants (initial age 9–13 years (mean 11.1  0.78) and 48.6% female) com-
pleted the study. No adverse events attributable to the products were reported during the
course of the study. The subject mean DQ (mm2 %), representing lesion volume, was 27.26 at
baseline. After 6 months of product use, the DQ values for the arginine-containing, positive
and negative control dentifrices were 13.46, 17.99 and 23.70 representing improvements
from baseline of 50.6%, 34.0% and 13.1%. After 6 months product use, the differences
between the pair wise comparisons for all three groups were statistically significant
( p < 0.01). The arginine-containing dentifrice demonstrated an improvement after only 3
months that was almost identical to that achieved by the conventional 1450 ppm fluoride
dentifrice after 6 months.
Conclusion: The new dentifrice containing 1.5% arginine, an insoluble calcium compound,
and 1450 ppm fluoride provides statistically significantly superior efficacy in arresting and
reversing buccal caries lesions to a conventional dentifrice containing 1450 ppm fluoride
# 2013 Elsevier Ltd. Open access under CC BY-NC-ND license.alone.* Corresponding author at: Colgate-Palmolive Dental Health Unit, Skelton House, Manchester Science Park, Lloyd St North, Manchester
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0300-5712 # 2013 Elsevier Ltd.
doi:10.1016/j.jdent.2010.04.004
Open access under CC BY-NC-ND license.
j o u r n a l o f d e n t i s t r y 4 1 s ( 2 0 1 3 ) s 2 2 – s 2 8 S231. Introduction
There is no doubt that the introduction of fluoride products,
such as dentifrice and mouth rinses, has played a significant
role in the dramatic decline in the prevalence and severity of
dental caries in many geographies, particularly in developed
countries.1,2 Despite this success, dental caries remains a
prevalent oral disease, and cavities remain a global public
health problem.1,3
The past two decades of caries research has significantly
advanced our knowledge of dental caries, and, in particular,
has identified that caries is a dynamic, multi-factorial disease
process involving the interface of the undisturbed plaque
biofilm and the tooth surface when dietary sugars are
present.4–6 The process begins when acid-producing species,
such as the mutans streptococci, within the undisturbed
plaque biofilm metabolize these dietary sugars to produce
lactic and other acids, causing initial de-mineralization, i.e.,
the first loss of calcium and phosphate ions from the
hydoxyapatite structure of the tooth’s enamel. This initial
step results in a reversible early caries lesion which can be re-
mineralized. Fluoride works by promoting re-mineralization
of this de-mineralized tissue, reversing the caries process and
adding calcium and phosphate ions back into the hydroxyap-
atite structure, as well as incorporating fluoride, as fluorapa-
tite, to strengthen themineral lattice.7,8 If de-mineralization is
left unchecked, however, dental caries can progress through
various irreversible stages of enamel breakdown to frank
cavitation.9
Importantly, this new knowledge has led to an under-
standing that caries is a disease continuum.1 This, in turn, has
begun to change clinical dentistry from a focus on restoration
of cavities to investigation of therapeutic approaches to arrest
or reverse the caries process by re-mineralizing initial enamel
or root caries lesions that are not cavitated.10 In large part,
however, such interventions have focussed on mechanical
plaque control measures to remove the biofilm and reduce
acid production by cariogenic bacteria, and treatment with
fluoride to facilitate re-mineralization and inhibit de-miner-
alization.11 Dentifrice is an ideal vehicle for fluoride because it
simultaneously facilitates plaque removal during brushing
and ensures effective delivery of fluoride for the treatment and
prevention of carious lesions. In fact, fluoride dentifrice is the
most effective, evidence-based caries preventive measure
available today.12
During the past decade, a new approach to the manage-
ment of dental caries has been identified and validated. This
new approach combines arginine and an insoluble calcium
compound with fluoride to complement and enhance the
effects of fluoride by targeting the first step in the caries
process, i.e., the first acid attack, modulating the metabolism
of the plaque biofilm, neutralizing plaque acids and, thereby,
reducing the harmful effects of the plaque biofilm.1,13 The
arginine is metabolized to ammonia through the arginine
deiminase pathway in non-pathogenic arginolytic organisms,
such as Streptococcus sanguis. In turn, this ammonia neutralizes
plaque acids and stabilizes the residual plaque biofilm,
preventing a shift in the oral flora to aciduric bacterial species
and maintaining a non-cariogenic plaque after sugarchallenge.1,13,14 Thus, the less acidic intra-oral pH encourages
re-mineralization and reduces de-mineralization.15 In addi-
tion, the insoluble calcium compound is able to provide free
calcium ions to supplement the re-mineralization pro-
cess.1,13,14,16‘
The anti-caries benefits of a new dentifrice containing 1.5%
arginine, an insoluble calcium compound, and 1450 ppm
fluoride, as sodium monofluorophosphate (MFP), have been
demonstrated in a series of clinical studies involving revers-
ible caries lesions in adults, as well as in children.17–20
In two studies, the ability of the new arginine-containing
dentifrice to re-mineralize non-cavitated primary root caries
lesions was evaluated. In one study, the new dentifrice was
compared to that of a positive control dentifrice containing
1450 ppm fluoride, as sodium fluoride, in a silica base, and a
fluoride-free, matched negative control. After 6 months use of
the new dentifrice, one lesion (0.7%) became worse and 61.7%
of subjects had lesions which hardened. In contrast, for the
positive and negative control dentifrices, 9.0% and 18.2% of
subjects became worse, and 56.0% and 27% improved,
respectively. The differences between the new arginine-
containing dentifrice and both the positive and negative
control dentifrices were statistically significant (p < 0.01).17 In
the other study, the new dentifrice was compared to that of a
matched positive control dentifrice containing 1450 ppm
fluoride alone. After 6 months use of the new dentifrice,
70.5% of subjects had lesions which hardened compared to
58.1% of subjects in the positive control group. The difference
in the number of lesions being hardened between the new
arginine-containing dentifrice and the positive control denti-
frices was statistically significant ( p < 0.05).18
In three studies, including the study reported in this paper,
the benefits of the new dentifrice containing 1.5% arginine, an
insoluble calcium compound, and 1450 ppm fluoride in
arresting and reversing buccal enamel carious lesions were
demonstrated using Quantitative Light-induced Fluorescence
(QLF) methods to measure changes in mineralization of
enamel lesions.19,20 The Quantitative Light-induced Fluores-
cence (QLF) method is based upon the principle that a tooth
fluoresces green when it is stimulated with blue light. Emitted
green light is scattered within an early lesion, when caries is
present, such that the overlying tooth surface appears dark
against a green background. By comparing the loss of
fluorescence, due to scattering in the lesion, to the background
level of fluorescence, both the area and degree of de-
mineralization (DF) of the lesion can be quantified. In addition,
the volume of the lesion (DQ) can be estimated by multiplying
the lesion area by the loss of fluorescence (DF). This method
has now been employed in a number of clinical studies.21–24
In one study, the new dentifrice was compared to two
matched dentifrices, one with neither fluoride nor arginine as
a negative control and the other a 1450 ppm fluoride only
dentifrice as a positive control. After 6 months use of the
products, the mean lesion size was reduced by 50.7% for the
arginine-containing dentifrice, 32.3% for the positive control
and 11.4% for the negative control. The differences between
the arginine-containing dentifrice and both the positive and
negative control dentifrices were statistically significant
(p < 0.01).19 In the other study, the new dentifrice was
compared to a matched 1450 ppm fluoride dentifrice as a
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Fig. 1 – Set up of the QLF system.
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size was reduced by 44.6% for the arginine-containing
dentifrice and 28.9% for the positive control. Again, the
differences between both the arginine-containing dentifrice
and the positive control dentifricewere statistically significant
(p < 0.05).20
Finally, a 2-year conventional caries clinical study has
proven that two dentifrices containing 1.5% arginine and
1450 ppm fluoride in a calcium base, one with di-calcium
phosphate and the other with calcium carbonate, are
significantly more effective in preventing the formation of
cavitated caries lesions than a dentifrice containing 1450 ppm
fluoride alone. Three trained and calibrated dentists examined
the children at baseline and after one and two years using the
National Institute of Dental Research Diagnostic Procedures
and Criteria. The number of decayed, missing, and filled teeth
(DMFT) and surfaces (DMFS) for the three study groups were
very similar at baseline, with no statistically significant
differences among groups. After one year, there were no
statistically significant differences in caries increments
among the three groups. After two years, the two groups
using the dentifrices containing 1.5% arginine, an insoluble
calcium compound and 1450 ppm fluoride had statistically
significantly (p < 0.02) lower DMFT increments (21.0% and
17.7% reductions, respectively) and DMFS increments (16.5%
and 16.5%) compared to the control dentifrice. The differences
between the two groups using the new dentifrices were not
statistically significant. The results of this pivotal clinical
study support the conclusion that dentifrices containing 1.5%
arginine, an insoluble calcium compound, and 1450 ppm
fluoride provide superior protection against caries lesion
cavitation to dentifrices containing 1450 ppm fluoride alone.25
The aim of this 6 month study was to confirm the
hypothesis that the new dentifrice containing 1.5% arginine
and 1450 ppm fluoride is more effective in arresting and
reversing naturally occurring buccal caries lesions in children
than a regular dentifrice containing fluoride alone. Three
dentifriceswere investigated: anarginine-containing dentifrice
containing 1.5% arginine, an insoluble calcium compound, and
1450 ppmfluoride, as sodiummonofluorophosphate, a positive
control dentifrice containing 1450 ppm fluoride, as sodium
fluoride, in a silica base and a matched negative control
dentifrice with neither fluoride nor arginine.2. Methods
This study was a randomised, controlled, double blind clinical
trial of 6 month’s duration which compared a new arginine-
containing dentifrice to both positive and negative controls.
The three products investigated in this study were1. Arginine-containing dentifrice: 1.5% arginine, an insoluble
calcium compound, and 1450 ppm fluoride as sodium
monofluorophosphate (Colgate-Palmolive Company, New
York, NY).2. Positive control: 1450 ppm fluoride as sodium fluoride in a
silica base (Colgate-Palmolive Company, New York, NY).3. Negative control: non-fluoride dentifrice with a matched
calcium base (Colgate-Palmolive Company, New York, NY).The study received ethical approval from the Institutional
Review Board of Sichuan Province Committee for Oral Health.
The study participants were from five primary schools in
Chengdu, Sichuan Province, China, which has a water supply
containing 0.3 ppmfluoride. The schoolswere selected to have
similar socio-demographic profiles and also on their ability to
provide supervised brushing to the participants. Participating
subjects were aged 9–13 years at the start of the study and had
to have at least one visible white spot lesion on the buccal
surface of one of the upper six anterior teeth. They were also
required to have a signed consent form from a parent or
guardian. Subjects meeting the screening criteria were
randomly allocated to groups by the study administrator.
After the baseline and 3 months examinations, two
individually labelled white laminated tubes of the assigned
dentifrice and a Colgate Extra Clean toothbrush (Colgate-
Palmolive, New York, NY, USA) were given to each study
participant. Only one type of dentifrice was assigned per
family and additional tubes of dentifrice were available on
request from participants. Participants were given oral
hygiene instruction and advised to brush at least twice per
day (morning and evening) with the toothbrush and dentifrice
supplied. During school days, participants brushed in the
afternoon with their allocated dentifrice for 2 min under the
supervision of the school nurse.
Assessments were performed at baseline, and after 3 and 6
months of product use, in the school nurse’s office. This room
was darkened to control ambient lighting. For each subject
between three and five views were taken of the upper anterior
teeth so that good quality images could be captured of each
lesion. Prior to image capture, the teeth were dried with
compressed air for five seconds. Imageswere captured using a
custom built, high resolution, fluorescence imaging system.
This has been described previously in some detail.26
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Fig. 2 – Disposition of subjects.
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stabilising unit (Fig. 1). This, together with video repositioning
software, enabled subjects to be accurately repositioned at
each visit. Images were acquired using QLF Patient software
(Inspektor Research Systems BV, Amsterdam, The
Netherlands). For the 3 and 6 months visits, the video
repositioning software was used with a grab level of 0.95.
Images were analysed to calculate lesion area and loss of
fluorescence using QLF 2.00 software (Inspektor Research
Systems BV). All images were taken by the same examiner.
2.1. Statistical analysis
The QLF software was used to calculate the area (mm2) and
percentage loss of fluorescence (DF%) of the lesion using a
threshold for difference of 5% from the reconstructed image.
The DF and area were used to calculate DQ (mm2 %) which
indicates the volume of the lesion.
The primary outcome for this study was the mean subject
DQ at the 6-month examination. The three study groups were
compared using a LinearModel controlling for baselineDQ and
number of lesions per subject. Other statistical comparisons
were based on a similar model with the baseline QLF metric
and number of lesions per subject as covariables. A Bonferroni
adjustment was applied to all pair wise comparisons.Table 1 – Subject mean (SD) QLF metrics (DF, Area and DQ) at b
number of lesions at baseline.
Group N lesions/subject Baseline
DF Area
1.5% arginine/1450 MFP 3.44 (1.19) 9.17
(1.96)
2.48
(1.79)
1450 NaF 3.29 (1.19) 9.24
(2.16)
2.60
(1.98)
Non-F 3.33 (1.17) 9.06
(1.82)
2.50
(1.86)3. Results
3.1. Reproducibility
At the baseline examinations, 27 randomly selected children
were examined using the QLF system and repeat examina-
tions were conducted 24 h later without using the video
repositioning (Vidrep) function. The Intra-class Correlation
Coefficient (ICC) between the two examinations was 0.95. In
addition, to check the reproducibility of the software analysis,
32 subjects were randomly selected and a repeat analysis
conducted after a 1-week interval. An ICC value of 0.93 was
reached for the DQ values.
3.2. Disposition of subjects
A total of 2983 children were consented to take part in the
study and were screened. Of these 463 satisfied the inclusion
and exclusion criteria andwere recruited into the study. At the
3-month examination, sixteen subjects were lost from study.
Of these, five transferred to another school; for eleven
subjects, images could not be captured at the time of each
scheduled assessment. At the 6-month examination, a further
nine subjects, who transferred to another school, were lost
from the study (Fig. 2).
A total of 438 children completed the study. Of these, 144
were in the arginine-containing dentifrice, 147 in the positive
control and 147 in the negative control groups. The children
were aged 9–13 years (mean 11.1  0.78) at the start of the
study and 48.6%were female.No adverse eventswere reported
in any of the study groups during the course of the study.
3.3. Clinical results
For each subject, a mean of 3.35 (1.18) lesions were imaged
(Table 1). Themaximumnumber of lesions per subject imaged
was six and minimum one. At the baseline examination, the
three study groups were well balanced with respect to all QLF
metrics with no statistically significant differences between
the groups (Table 1).
3.4. Three months
For DF, the baseline mean was 9.16% and after 3 months was
8.23, 8.50 and 8.67 for the arginine-containing, positive andaseline and 3 and 6 months for the three study groups and
3 months 6 months
DQ DF Area DQ DF Area DQ
26.75
(25.91)
8.24
(1.83)
1.79
(1.44)
17.64
(18.12)
7.95
(1.82)
1.40
(1.14)
13.12
(13.08)
28.00
(26.83)
8.56
(2.12)
2.05
(1.77)
21.24
(22.75)
8.43
(2.07)
1.83
(1.50)
18.46
(18.43)
27.02
(29.23)
8.60
(1.83)
2.29
(2.14)
24.32
(29.23)
8.48
(2.24)
2.16
(2.24)
23.54
(29.84)
Table 2 – Baseline adjusted subject mean (SE) QLF metrics (DF, Area and DQ) at 3 and 6 months for the three study groups
with number of lesions at baseline as covariable.
Group Adjusted 3 months Adjusted 6 months
DF Area DQ DF Area DQ
1.5% arginine/1450 MFP 8.23 (0.11) 1.83 (0.08) 18.00 (1.07) 7.94 (0.12) 1.44 (0.09) 13.46 (1.07)
1450 NaF 8.50 (0.11) 1.99 (0.08) 20.71 (1.06) 8.37 (0.12) 1.78 (0.09) 17.99 (1.06)
Non-F 8.67 (0.11) 2.31 (0.08) 24.50 (1.06) 8.56 (0.12) 2.18 (0.09) 23.70 (1.05)
Baseline mean 9.16 2.53 27.26 9.16 2.53 27.26
N lesions 3.35
j o u rn a l o f d e n t i s t r y 4 1 s ( 2 0 1 3 ) s 2 2 – s 2 8S26negative control dentifrices, respectively (Table 2). For lesion
area, the baseline mean was 2.53 mm2 compared to 1.83, 1.99
and 2.31 for the arginine-containing, positive and negative
control dentifrices, respectively, at the 3months examination.
For DQ, the baseline mean was 27.26 mm2 % and after 3
months was reduced to 18.00, 20.71 and 24.50 representing
improvements from baseline of 34.0%, 24.0% and 10.1% for the
arginine-containing, positive and negative control dentifrices,
respectively. The differences between the negative control
dentifrice and the both the arginine-containing and positive
control dentifrices were statistically significant.
3.5. Six months
For the arginine-containing, positive and negative control
dentifrices, the baseline adjusted mean DF values at the 6-
month examination were 7.94, 8.37 and 8.56 and for area were
1.44, 1.78 and 2.18. Compared to the baseline mean value for
DQ of 27.26 mm2 %, the values at 6 months had reduced for DQ
to 13.46, 17.99 and 23.70 (Table 2). This represents improve-
ments from baseline of 50.6%, 34.0% and 13.1% for the
arginine-containing dentifrice, and the positive and negative
control dentifrices, respectively. The baseline adjusted DQ
data are shown in Fig. 3. It can be seen that the improvement
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Fig. 3 – Mean DQ (representing lesion volume in mm2 %)
outcomes at baseline, 3 and 6 months with 95%
confidence intervals.in the arginine-containing dentifrice group at 3 months is
comparable to that at 6 months for the fluoride-containing
positive control dentifrice. ForDQ, the differences between the
negative control group and both the arginine-containing
dentifrice and the positive control groups were statistically
significant (p < 0.001). Further, the difference between the
arginine-containing dentifrice andpositive control groupswas
also statistically significant (p = 0.003). Fig. 4 plots the total
percentage of subjects with improvements from baseline as a
function of the percentage mean improvement for the three
groups. It can be seen that 88.9% of subjects showed some
improvement (reduction in mean DQ) in the arginine-contain-
ing dentifrice group compared to 78.9% in the positive control
and 70.7% in the negative control groups. In nearly half (47.2%)
of the subjects using the arginine-containing dentifrice, the
lesions reduced in size by 50% ormore compared to only 39.5%
of the subjects in the positive control group and 34% in the
negative control group.4. Discussion
This study has provided further clinical evidence that a new
dentifrice containing 1.5% arginine, an insoluble calcium
[(Fig._4)TD$FIG]
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Fig. 4 – Total frequency of subjects showing a reduction in
mean lesion size bay at least 0–50% after 6 months product
use for the three study groups.
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efficacy that is significantly superior to that of conventional
1450 ppm fluoride dentifrices. After 6 months use of the
arginine-containing product, lesions had reduced inmean size
frombaselineby50.6%compared toonly34.0%reductionafter 6
months use of the conventional 1450 pm fluoride dentifrice.
34.0% reduction in lesion size was achieved after just 3months
use of the arginine-containing dentifrice indicating that lesions
were re-mineralizing twice as quickly with the arginine-
containing dentifrice as with the conventional fluoride denti-
frice. Thus, this study confirmed the hypothesis that the new
dentifrice containing 1.5% arginine, an insoluble calcium
compound, and 1450 ppm fluoride is more effective than a
positive control dentifrice containing 1450 ppm fluoride alone
in arresting and reversing naturally occurring buccal caries
lesions in children.
In the two other studies conducted on this new dentifrice,
using the QLF method, very similar results were observed,
with reductions in lesion area of approximately 50% and 45%
in the two groups using the dentifrice containing 1.5%
arginine, and insoluble calcium compound, and 1450 ppm
fluoride, and approximately 32% and 29% in the two groups
using the 1450 ppm fluoride positive control dentifrices.19,20 In
the one of the studies, a fluoride-free matched negative
control dentifrice was also included to assess the effect of
brushing with dentifrice without fluoride. An approximately
11% reduction in lesion size was attributable to improved
plaque control at the 6 months examination in that study.19
The results of these studies show that the new arginine-
containing dentifrice provides an enhancement in efficacy in
reversing early enamel lesions over dentifrices with fluoride
alone that is numerically comparable to the enhancement that
a 1450 ppm fluoride dentifrice provides over a fluoride-free
dentifrice. As the clinical efficacy of fluoride toothpaste in
preventing cavity formation is well established in traditional
caries clinical trials (fluoride compared to non-fluoride tooth-
paste),12 the clinical implication of these results is that, with
continued use, the arginine-containing dentifrice will provide
substantially more effective cavity prevention than dentifrices
containing fluoride alone, by virtue of its enhanced ability to
arrest and reverse early lesions, thereby preventing their
progression to irreversible lesions and cavities.
Based upon the results of the three studies conducted on
the new arginine-containing dentifrice, as well as of several
studies validating the QLF method by distinguishing products
that had previously been investigated in conventional 2–4
years caries clinical studies, it is apparent that the use of QLF
in studies of early coronal caries significantly improves the
ability to discriminate between anti-caries products enabling
the studies to be conducted effectively in shorter time periods
with fewer participants. It further appears that the ability of
products designed to enhance the re-mineralization of initial
carious lesions is measured accurately, prior to stages of
cavitation, enabling quantification of their efficacy under
conditions most appropriate to their mechanisms of action. It
is known that therapeutic treatment of initial carious lesions
is both possible and practical, and by employing sophisticated
detection and measurement methods, such as QLF, this
approach is facilitated and outcomes can be monitored so
that participants receive optimum, minimally invasivetreatment. Thus, the QLF method has proven to be a powerful
tool in the caries clinical hierarchy providing unique insights
regarding efficacy and mechanism of action of anti-caries
products on early coronal caries lesions that complement and
augment those generated in conventional 2-year caries
studies of cavitation.5. Conclusion
It is concluded that both fluoride-containing dentifrices are
significantly better at arresting and reversing buccal caries
lesions than the non-fluoride dentifrice.More importantly, the
new dentifrice containing 1.5% arginine, an insoluble calcium
compound, and 1450 ppm fluoride provides significantly
greater benefit in arresting and reversing buccal caries lesions
than the conventional fluoride dentifrice.Conflict of interest statement
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